UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Vedolizumab in IBD–Lessons From Real-world Experience; A Systematic Review and Pooled Analysis

Journal of Crohn's and colitis, 2018-01, Vol.12 (2), p.245-257

2018

Volltextzugriff (PDF)

Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence

Digestive and liver disease, 2019-09, Vol.51 (9), p.1232-1240

2019

Volltextzugriff (PDF)

Patency Capsule: A Novel Independent Predictor for Long-Term Outcomes Among Patients With Quiescent Crohn's Disease

The American journal of gastroenterology, 2023-06, Vol.118 (6), p.1019-1027

2023

Volltextzugriff (PDF)

Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience

Inflammatory bowel diseases, 2017-03, Vol.23 (3), p.404-408

2017

Volltextzugriff (PDF)

Long-term outcome of ulcerative proctitis

United European gastroenterology journal, 2020-10, Vol.8 (8), p.847-848

2020

Volltextzugriff (PDF)

Terminal Ileum Thickness During Maintenance Therapy Is a Predictive Marker of the Outcome of Infliximab Therapy in Crohn Disease

Inflammatory bowel diseases, 2020-10, Vol.26 (10), p.1619-1625

2020

Volltextzugriff (PDF)

Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment With TNFα Antagonists

Frontiers in immunology, 2019-12, Vol.10, p.2921-2921

2019

Volltextzugriff (PDF)

Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases

Therapeutic advances in gastroenterology, 2022-01, Vol.15, p.17562848211068659-17562848211068659

2022

Volltextzugriff (PDF)

Infliximab levels and antibodies in IBD-related peripheral arthralgia

International journal of colorectal disease, 2020-06, Vol.35 (6), p.1141-1148

2020

Volltextzugriff (PDF)

Machine learning for prediction of intra-abdominal abscesses in patients with Crohn’s disease visiting the emergency department

Therapeutic advances in gastroenterology, 2021, Vol.14, p.17562848211053114-17562848211053114

2021

Volltextzugriff (PDF)

Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening

Therapeutic advances in gastroenterology, 2022-03, Vol.15, p.17562848221083395-17562848221083395

2022

Volltextzugriff (PDF)

A novel PillCam Crohn’s capsule score (Eliakim score) for quantification of mucosal inflammation in Crohn’s disease

United European gastroenterology journal, 2020-06, Vol.8 (5), p.544-551

2020

Volltextzugriff (PDF)

Acute Chest Pain as an Infusion Reaction to Vedolizumab

Case reports in gastroenterology, 2022-05, Vol.16 (2), p.430-434

2022

Volltextzugriff (PDF)

Predictors of mortality in inflammatory bowel disease patients treated for pneumonia

Therapeutic advances in gastroenterology, 2020, Vol.13, p.1756284820939453-1756284820939453

2020

Volltextzugriff (PDF)

Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease—The Israeli real world experience

Digestive and liver disease, 2019-01, Vol.51 (1), p.68-74

2019

Volltextzugriff (PDF)

Do Vedolizumab trough Levels Predict the Outcome of Subsequent Therapy in Inflammatory Bowel Disease?

Biomedicines, 2023-05, Vol.11 (6), p.1553

2023

Volltextzugriff (PDF)

Editorial: is vedolizumab effective for perianal Crohn's disease?

Alimentary pharmacology & therapeutics, 2020-05, Vol.51 (9), p.912-913

2020

Volltextzugriff (PDF)

Significance of low level infliximab in the absence of anti-infliximab antibodies

World journal of gastroenterology : WJG, 2015-02, Vol.21 (6), p.1907-1914

2015

Volltextzugriff (PDF)

Infliximab discontinuation in patients with ulcerative colitis

The lancet. Gastroenterology & hepatology, 2021-06, Vol.6 (6), p.412-413

Ungar, Bella

2021

Volltextzugriff (PDF)

Does pan‐enteric capsule endoscopy obviate magnetic resonance entero‐colonography in suspected Crohn's disease?

United European gastroenterology journal, 2022-11, Vol.10 (9), p.917-918

2022

Volltextzugriff (PDF)

Advances in the development of new biologics in inflammatory bowel disease

Annals of gastroenterology, 2016-01, Vol.29 (3), p.243-248

2016

Volltextzugriff (PDF)

Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases

Clinical gastroenterology and hepatology, 2016-04, Vol.14 (4), p.550-557.e2

2016

Volltextzugriff (PDF)

The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab

Gut, 2014-08, Vol.63 (8), p.1258-1264

2014

Volltextzugriff (PDF)

Vedolizumab in IBD–Lessons From Real-world Experience; A Systematic Review and Pooled Analysis

Journal of Crohn's and colitis, 2018-01, Vol.12 (2), p.245-257

2018

Volltextzugriff (PDF)

Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab

Clinical gastroenterology and hepatology, 2015-03, Vol.13 (3), p.522-530.e2

2015

Volltextzugriff (PDF)

1 – 25 von 109

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(107)
Mit Volltextzugriff
(105)

Publikationsform

Artikel
(108)
Berichte
(1)

Sprache

Englisch
(109)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(75)
Science & Technology
(75)
Gastroenterology & Hepatology
(62)
Humans
(41)
Inflammatory Bowel Disease
(31)
Female
(27)
Adult
(25)
Male
(23)
Crohn's Disease
(19)
Ulcerative Colitis
(18)
Retrospective Studies
(17)
Young Adult
(17)
Inflammatory Bowel Diseases - Drug Therapy
(16)
Infliximab
(16)
Crohn Disease - Drug Therapy
(15)
Middle Aged
(15)
Patients
(15)
Gastroenterology And Hepatology
(14)
Ibd
(14)
Treatment Outcome
(14)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Vedolizumab in IBD–Lessons From Real-world Experience; A Systematic Review and Pooled Analysis

Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence

Patency Capsule: A Novel Independent Predictor for Long-Term Outcomes Among Patients With Quiescent Crohn's Disease

Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience

Long-term outcome of ulcerative proctitis

Terminal Ileum Thickness During Maintenance Therapy Is a Predictive Marker of the Outcome of Infliximab Therapy in Crohn Disease

Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment With TNFα Antagonists

Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases

Infliximab levels and antibodies in IBD-related peripheral arthralgia

Machine learning for prediction of intra-abdominal abscesses in patients with Crohn’s disease visiting the emergency department

Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening

A novel PillCam Crohn’s capsule score (Eliakim score) for quantification of mucosal inflammation in Crohn’s disease

Acute Chest Pain as an Infusion Reaction to Vedolizumab

Predictors of mortality in inflammatory bowel disease patients treated for pneumonia

Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease—The Israeli real world experience

Do Vedolizumab trough Levels Predict the Outcome of Subsequent Therapy in Inflammatory Bowel Disease?

Editorial: is vedolizumab effective for perianal Crohn's disease?

Significance of low level infliximab in the absence of anti-infliximab antibodies

Infliximab discontinuation in patients with ulcerative colitis

Does pan‐enteric capsule endoscopy obviate magnetic resonance entero‐colonography in suspected Crohn's disease?

Advances in the development of new biologics in inflammatory bowel disease

Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases

The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab

Vedolizumab in IBD–Lessons From Real-world Experience; A Systematic Review and Pooled Analysis

Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab

Suchergebnisse filtern